Skip to main content

remestemcel-L

Generic: remestemcel-L·Brand: Ryoncil

remestemcel-L: 3 clinical trials tracked.

remestemcel-L evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about remestemcel-L, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Ulcerative Colitis

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

NCT04456439Registry updated 2025-10-31
No longer available
Expanded AccessMesoblast International Sàrl

A Phase IB/IIA Study of Remestemcel-L, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative Colitis

NCT04543994Registry updated 2026-04-16·Phase 1/Phase 2
Terminated

Primary endpoint: Treatment related adverse events

InterventionalRandomizedsingle7 targetStarted 2020-11Completion 2023-111 site · United StatesThe Cleveland Clinic

A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583Registry updated 2026-04-16·Phase 1/Phase 2
Terminated

Primary endpoint: Treatment related adverse events

InterventionalRandomizedsingle7 targetStarted 2020-11Completion 2023-111 site · United StatesThe Cleveland Clinic